Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 146Rituximab 138fludarabine phosphate 111Mycophenolic Acid 69Peripheral Blood Stem Cell Transplantation 63fludarabine 59Tacrolimus 58Whole-Body Irradiation 51venetoclax 46Busulfan 46ibrutinib 45Cyclosporine 42Lenalidomide 41Filgrastim 41Alemtuzumab 41Melphalan 40Radiotherapy 39obinutuzumab 37Antilymphocyte Serum 35Etoposide 33Methotrexate 32ofatumumab 29acalabrutinib 26Bendamustine Hydrochloride 24sargramostim 22Methylprednisolone 18Cytarabine 18zanubrutinib 17Pentostatin 17Granulocyte Colony-Stimulating Factor 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphocytic, Chronic, B-Cell × sapacitabine × Clear all
NCT01253460 2019-09-06

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

M.D. Anderson Cancer Center

Phase 2 Terminated
18 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡